Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers
Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
